This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
The patient is informed of and voluntarily signs the informed consent form (ICF).
Age ≥18 years, regardless of sex.
Confirmed diagnosis of primary light-chain (AL) amyloidosis, in accordance with the Guidelines for the Diagnosis and Treatment of Systemic Light-chain Amyloidosis (2021 Revision).
Difference between involved and uninvolved free light chains (dFLC) ≥50 mg/L, or
None